Frontiers in Pharmacology · 2022 · 23 citations · 32 references
Life SciencesCardiologyPharmacologyCell SignalingMetabolismSignal TransductionCardiovascular DiseaseCardiovascular PhysiologyCoronary Artery DiseaseHeart FailureIschemic Heart DiseaseMetabolic SignalingCardiac Hypertrophy SignalingHif-1 SignalingMetabolic ModulationMetabolic TherapiesMyocardial Energy MetabolismMyocardial MetabolismProtective TreatmentsProtein Expression Levels
Coronary artery disease (CAD) and cardiac hypertrophy (CH) are two main causes of ischemic heart disease. Acute CAD may lead to left ventricular hypertrophy (LVH). Long-term and sustained CH is harmful and can gradually develop into cardiac insufficiency and heart failure. It is known that metformin (Met) can alleviate CH; however, the molecular mechanism is not fully understood. Herein, we used high-fat diet (HFD) rats and H9c2 cells to induce CH and clarify the potential mechanism of Met on CH. We found that Met treatment significantly decreased the cardiomyocyte size, reduced lactate dehydrogenase (LDH) release, and downregulated the expressions of hypertrophy markers ANP, VEGF-A, and GLUT1 either in vivo or in vitro . Meanwhile, the protein levels of HIF-1α and PPAR-γ were both decreased after Met treatment, and administrations of their agonists, deferoxamine (DFO) or rosiglitazone (Ros), markedly abolished the protective effect of Met on CH. In addition, DFO treatment upregulated the expression of PPAR-γ, whereas Ros treatment did not affect the expression of HIF-1α. In conclusion, Met attenuates CH via the HIF-1α/PPAR-γ signaling pathway.
32
GDF15 mediates the effects of metformin on body weight and energy balance
Anthony P. Coll, Michael Chen, Pranali Taskar et al. · Nature · 2019 · 570 citations · Full text
SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy
Xiaoqiang Tang, Xiaofeng Chen, Nan-Yu Wang et al. · Circulation · 2017 · 350 citations